Global Search | Novartis

Hide Filters

Showing 2980 results

Ad hoc release / Oct 29, 2024

Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben

Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +10% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +20% (kWk, +17% USD)Das Umsatzwachstum…
Press release / Oct 27, 2024

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of…
Press release / Oct 24, 2024

Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and…
Press release / Oct 18, 2024

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant…
Press release / May 31, 2024

Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria

Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s…
Press release / May 25, 2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (…
Press release / May 25, 2024

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical…
Press release / May 16, 2024

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the…
Press release / May 15, 2024

Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA

Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the…
Press release / May 02, 2024

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline

Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancerMariana Oncology is a preclinical-stage biotechnology company focused…